# A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

> **NCT00110305** · PHASE2 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 368 (actual)

## Conditions studied

- Human Immunodeficiency Virus Type 1

## Interventions

- **DRUG:** TMC278 25 mg
- **DRUG:** TMC278 75 mg
- **DRUG:** TMC278 150 mg
- **DRUG:** Efavirenz
- **DRUG:** Non-nucleoside reverse transcriptase inhibitor (NRTIs)

## Key facts

- **NCT ID:** NCT00110305
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 368 (ACTUAL)
- **Last updated:** 2014-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00110305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00110305, "A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00110305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*